Biblio

Export 29 results:
Szerző [ Cím(Desc)] Típus Év
Szűrők: Az Utónév Első Betűje is S  [Minden szűrő visszaállítása]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, et al.. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res [Internet]. 2009;104(11):1302 - 12. http://view.ncbi.nlm.nih.gov/pubmed/19443835PDF ikon Andrey Anisimov et al., Circulation Research 2009 (8.03 MB)PDF ikon Andrey Anisimov et al., Circulation Research 2009, supplement (5.9 MB)
Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, et al.. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res [Internet]. 2001;88(6):623 - 9. http://view.ncbi.nlm.nih.gov/pubmed/11282897PDF ikon Bernd Enholm et al., Circulation Research 2001 (2.93 MB)
Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, et al.. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J [Internet]. 2002;16(9):1041 - 9. http://view.ncbi.nlm.nih.gov/pubmed/12087065PDF ikon Anne Saaristo et al., FASEB Journal 2002 (966.08 KB)
C
Saharinen P, Helotera H, Miettinen J, Norrmen C, D'Amico G, Jeltsch M, et al.. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Genes Dev [Internet]. 2010;24(9):875 - 80. http://view.ncbi.nlm.nih.gov/pubmed/20439428PDF ikon Pipsa Saharinen et al., Genes & Development 2010 (1.2 MB)PDF ikon Pipsa Saharinen et al., Genes & Development 2010, supplement (9.15 MB)
H
Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al.. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (80- ) [Internet]. 1997;276(5317):1423 - 5. http://view.ncbi.nlm.nih.gov/pubmed/9162011PDF ikon Michael Jeltsch et al., Science 1997 (293.65 KB)
I
Veikkola T, Lohela M, Ikenberg K, Mäkinen T, Korff T, Saaristo A, et al.. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J [Internet]. 2003;17(14):2006 - 13. http://view.ncbi.nlm.nih.gov/pubmed/14597670PDF ikon Tanja Veikkola et al., FASEB Journal 2006 (598.77 KB)
K
Jha SKumar, Rauniyar K, Chronowska E, Mattonet K, Maina EWairimu, Koistinen H, et al.. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. eLife [Internet]. 2019;8:e44478. https://elifesciences.org/articles/44478PDF ikon Jha & Rauniyar et al. 2019 (3.84 MB)
L
Gucciardo E, Lehti TA, Korhonen A, Salvén P, Lehti K, Jeltsch M, et al.. Lymphatics and the eye. [Finnish]. Duodecim Lääketieteellinen Aikakauskirja [Internet]. 2020;136(16):1777-1788. https://www.duodecimlehti.fi/lehti/2020/16/duo15739PDF ikon Gucciardo et al. Lymphatics and the Eye (English version). (3.31 MB)
O
Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, et al.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827PDF ikon Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB)PDF ikon Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB)
P
Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734PDF ikon Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
Lackner M, Schmotz C, Jeltsch M. The Proteolytic Activation of Vascular Endothelial Growth Factor-C. Lymphologie in Forschung und Praxis [Internet]. 2019;23(2):88 - 98. https://doi.org/10.5281/zenodo.3629263PDF ikon English version: Lackner et al. 2019 (2.94 MB)PDF ikon German version: Lackner et al. 2019 (673.37 KB)
Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, et al.. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J [Internet]. 1997;16(13):3898 - 911. http://view.ncbi.nlm.nih.gov/pubmed/9233800PDF ikon Vladimir Joukov et al., EMBO Journal 1997 (729.21 KB)
Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, et al.. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J [Internet]. 1997;16(13):3898 - 911. http://view.ncbi.nlm.nih.gov/pubmed/9233800PDF ikon Vladimir Joukov et al., EMBO Journal 1997 (729.21 KB)
R
Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, et al.. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699PDF ikon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB)PDF ikon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB)
Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, et al.. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699PDF ikon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB)PDF ikon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB)
S
Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, et al.. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J [Internet]. 2001;20(6):1223 - 31. http://view.ncbi.nlm.nih.gov/pubmed/11250889PDF ikon Tanja Veikkola et al., EMBO Journal 2001 (491.14 KB)
Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, et al.. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. In Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Miami Beach, Florida; 2001. PDF ikon Jussila et al., 2001 (279.47 KB)
Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, et al.. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010;107(6):2425 - 30. http://view.ncbi.nlm.nih.gov/pubmed/20145116PDF ikon Veli-Matti Leppänen et al. PNAS 2010 (1 MB)PDF ikon Veli-Matti Leppänen et al. PNAS 2010, supporting information (2.23 MB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF ikon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF ikon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
V
Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, et al.. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A [Internet]. 1998;95(20):11709 - 14. http://view.ncbi.nlm.nih.gov/pubmed/9751730PDF ikon Birgitta Olofsson et al., PNAS 1998 (470.59 KB)
Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al.. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646PDF ikon Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB)PDF ikon Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB)PDF ikon Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB)
Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229PDF ikon Marc Achen et al., PNAS 1998 (447.59 KB)
Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J Biol Chem [Internet]. 2006;281(17):12187 - 95. http://view.ncbi.nlm.nih.gov/pubmed/16505489PDF ikon Michael Jeltsch et al., The Journal of Biological Chemistry 2006 (1.04 MB)PDF ikon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 1 (1.01 MB)PDF ikon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 2 (596.06 KB)PDF ikon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 3 (738.98 KB)PDF ikon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 4 (710.03 KB)PDF ikon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 5 (163.64 KB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF ikon Maija Bry et al., Circulation 2010 (2.23 MB)PDF ikon Maija Bry et al., Circulation 2010, supplement (17.77 MB)

Oldalak